Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out daily tasks such as eating ...
Studies in primate models and patients with Parkinson's disease have shown that ... or by modifying the pharmacokinetic profile of the drug by administering it in combination with a catechol ...